Finance
Novo-Backed Biotech Hemab Seeks to Raise $212 Million in US IPO
Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company, is seeking to raise as much as $212 million in a US initial public offering.
B
Bloomberg
April 27, 2026·1 min read
Image: Bloomberg
Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company, is seeking to raise as much as $212 million in a US initial public offering.
Original article
Novo-Backed Biotech Hemab Seeks to Raise $212 Million in US IPO
Published by Bloomberg